The Quarterly Results page of Dai Ichi Karkaria Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...